Prelude therapeutics presents new data from smarca degrader portfolio at the 36th eortc-nci-aacr symposium

– interim data from ongoing trial of prt3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (nsclc)

NCI Ratings Summary

NCI Quant Ranking